109. Preexisting Resistance and Week 48 Virologic Outcomes After Switching to B/F/TAF in African American Adults with HIV

BACKGROUND: The BRAAVE 2020 study is evaluating the safety and efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among virologically suppressed Black adults with HIV. At Week (W) 24, 0.6% (2/328) on B/F/TAF vs 1.8% (3/165) who stayed on their baseline 3 drug regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreatta, Kristen, D’Antoni, Michelle L, Chang, Silvia, Parvangada, Aiyappa, Blair, Christiana, Collins, Sean E, White, Kirsten L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777761/
http://dx.doi.org/10.1093/ofid/ofaa439.419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777761/
http://dx.doi.org/10.1093/ofid/ofaa439.419

Ejemplares similares